Owkin to Build AI Agents for Sanofi
Sanofi has signed a multi-year deal with Owkin to build AI agents on its K Pro platform, targeting drug discovery and development. The deal signals a shift among major pharma players from classic predictive models toward agents that autonomously carry out research tasks. The open question: how long before an actual drug emerges from this pipeline.
practitioners › Owkin K Pro, agentic biopharma platform, collaboration announced June 5, 2026, multi-year contract with Sanofi.
Owkin / Sanofi →